Growth Hormone in Combination with Bisphosphonate Treatment in Osteogenesis Imperfecta

Bone ◽  
2010 ◽  
Vol 46 ◽  
pp. S18-S19
Author(s):  
Francesco Doro ◽  
Paolo Cavarzere ◽  
Elena Monti ◽  
Giacomo Venturi ◽  
Silvano Adami ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Osteogenesis Imperfecta ◽  
Bisphosphonate Treatment

Growth and Growth Hormone Use in Osteogenesis Imperfecta

2014 ◽  
pp. 267-280 ◽  
Author(s):  
Emily L. Germain-Lee ◽  
Douglas J. DiGirolamo ◽  
Horacio Plotkin
Keyword(s):  
Growth Hormone ◽  
Osteogenesis Imperfecta ◽  
Hormone Use

scholarly journals Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates

2015 ◽  
Vol 15 (3) ◽  
pp. 313-320 ◽  
Author(s):  
Heidi Arponen ◽  
Ilkka Vuorimies ◽  
Jari Haukka ◽  
Helena Valta ◽  
Janna Waltimo-Sirén ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Cranial Base ◽  
Basilar Invagination ◽  
Craniocervical Junction ◽  
Normative Values ◽  
Bisphosphonate Treatment ◽  
Basilar Impression ◽  
Duration Of Treatment ◽  
Cross Sectional ◽  
Kaplan Meier

OBJECT Cranial base pathology is a serious complication of osteogenesis imperfecta (OI). Our aim was to analyze whether bisphosphonate treatment, used to improve bone strength, could also prevent the development of craniocervical junction pathology (basilar impression, basilar invagination, or platybasia) in children with OI. METHODS In this single-center retrospective study the authors analyzed the skull base morphology from lateral skull radiographs and midsagittal MR images (total of 94 images), obtained between the ages of 0 and 25 years in 39 bisphosphonate-treated OI patients. The results were compared with age-matched normative values and with findings in 70 OI patients who were not treated with bisphosphonates. In addition to cross-sectional data, longitudinal data were available from 22 patients with an average follow-up period of 7.6 years. The patients, who had OI types I, III, IV, VI, and VII, had been treated with zoledronic acid, pamidronate, or risedronate for 3.2 years on average. RESULTS Altogether 33% of the 39 bisphosphonate-treated patients had at least 1 cranial base anomaly, platybasia being the most prevalent diagnosis (28%). Logistic regression analysis suggested a higher risk of basilar impression or invagination in patients with severe OI (OR 22.04) and/or older age at initiation of bisphosphonate treatment (OR 1.45), whereas a decreased risk was associated with longer duration of treatment (OR 0.28). No significant associations between age, height, or cumulative bisphosphonate dose and the risk for cranial base anomaly were detected. In longitudinal evaluation, Kaplan-Meier curves suggested delayed development of cranial base pathology in patients treated with bisphosphonates but the differences from the untreated group were not statistically significant. CONCLUSIONS These findings indicate that cranial base pathology may develop despite bisphosphonate treatment. Early initiation of bisphosphonate treatment may delay development of craniocervical junction pathology. Careful followup of cranial base morphology is warranted, particularly in patients with severe OI.

Early bisphosphonate treatment in infants with severe osteogenesis imperfecta

2006 ◽  
Vol 149 (2) ◽  
pp. 174-179 ◽  
Author(s):  
Franco Antoniazzi ◽  
Giorgio Zamboni ◽  
Silvana Lauriola ◽  
Luisa Donadi ◽  
Silvano Adami ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Bisphosphonate Treatment

Fracture during Intravenous Bisphosphonate Treatment in a Child with Osteogenesis Imperfecta: An Argument for a More Frequent, Low-Dose Treatment Regimen

2014 ◽  
Vol 81 (3) ◽  
pp. 204-210 ◽  
Author(s):  
Andrew Biggin ◽  
Julie N. Briody ◽  
Elizabeth Ormshaw ◽  
Karen K.Y. Wong ◽  
Bruce H. Bennetts ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Treatment Regimen ◽  
Low Dose ◽  
Bisphosphonate Treatment ◽  
Dose Treatment ◽  
Intravenous Bisphosphonate

Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle

2018 ◽  
Vol 177 (6) ◽  
pp. 891-902 ◽  
Author(s):  
Argerie Tsimicalis ◽  
Madalina Boitor ◽  
Catherine E. Ferland ◽  
Frank Rauch ◽  
Sylvie Le May ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Osteogenesis Imperfecta ◽  
Children And Adolescents ◽  
Treatment Cycle ◽  
Bisphosphonate Treatment

Osteotomy Healing in Children With Osteogenesis Imperfecta Receiving Bisphosphonate Treatment

2015 ◽  
Vol 30 (8) ◽  
pp. 1362-1368 ◽  
Author(s):  
Emad A Anam ◽  
Frank Rauch ◽  
Francis H Glorieux ◽  
François Fassier ◽  
Reggie Hamdy
Keyword(s):  
Osteogenesis Imperfecta ◽  
Bisphosphonate Treatment

Growth hormone effect on bone mineral density in a girl with osteogenesis imperfecta - a case presentation

2019 ◽  
Author(s):  
Sofia Leka ◽  
Fani Athanasouli ◽  
Elpis Vlachopapadopoulou ◽  
Artemis Doulgeraki ◽  
Vassilios Petrou ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Growth Hormone ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Mineral Density ◽  
Case Presentation ◽  
Hormone Effect

Bisphosphonate treatment and the characteristics of femoral fractures in children with osteogenesis imperfecta

2015 ◽  
Author(s):  
Ilkka Vuorimies ◽  
Mervi Mayranpaa ◽  
Helena Valta ◽  
Heikki Kroger ◽  
Sanna Toiviainen-Salo ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Femoral Fractures ◽  
Bisphosphonate Treatment ◽  
Fractures In Children

scholarly journals Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment

2017 ◽  
Vol 32 (5) ◽  
pp. 1034-1039 ◽  
Author(s):  
Pamela Trejo ◽  
François Fassier ◽  
Francis H Glorieux ◽  
Frank Rauch
Keyword(s):  
Osteogenesis Imperfecta ◽  
Bisphosphonate Treatment ◽  
Femur Fractures
Sign in / Sign up

Export Citation Format

Share Document